scFv(Control)-41BB-CD3zeta CAR-T Lentivirus

The scFv(Control)-41BB-CD3zeta CAR-T Lentivirus represents a critical reagent in the field of adoptive immunotherapy, specifically designed to facilitate the rigorous evaluation of Chimeric Antigen Receptor (CAR) T-cell performance. This lentiviral vector integrates a second-generation CAR architecture comprising a non-binding “control” single-chain variable fragment (scFv), a 4-1BB (CD137) costimulatory endodomain, and a CD3ζ intracellular signaling domain. Unlike target-specific CARs, the control scFv is engineered to lack affinity for known cellular antigens, ensuring that the CAR-T cells remain inactive upon contact with target tissues. This configuration allows for the isolated study of the signaling backbone’s behavior and the viral vector’s influence on T-cell physiology. The use of a lentiviral delivery platform guarantees efficient genomic integration, leading to robust and stable expression of the CAR construct across multiple cell generations.

This lentivirus is primarily utilized as a negative control to delineate antigen-specific activation from baseline cellular responses in preclinical CAR-T development. It is essential for quantifying non-specific cytotoxicity and cytokine production, such as TNF-alpha or IFN-gamma, in both in vitro co-culture assays and in vivo xenograft models. By employing this control, researchers can effectively verify that observed anti-tumor activity is strictly dependent on the binding of the specific scFv to its intended ligand. Additionally, the scFv(Control)-41BB-CD3zeta variant is an ideal tool for benchmarking transduction efficiency, monitoring T-cell exhaustion markers associated with the 4-1BB domain, and optimizing the manufacturing processes of T-cell products. Its inclusion in experimental designs ensures the accuracy of data interpretation, helping to filter out artifacts related to the transduction procedure or the presence of the intracellular signaling complex itself.